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Abstract 
Primary cutaneous B-cell lymphomas (PCBCL) are 
a heterogeneous group of mature B-cells neoplasms 
that present in the skin without evidence of nodal or 
systemic involvement. The clinical and pathologic 
features of PCBCL differ significantly from the 
equivalent nodal lymphomas. Three main subtypes 
of PCBCL are recognized by the 2016 revised WHO 
classification. Studies have shown that PCBCLs are 
characterized by distinct immunophenotypic 
features, chromosomal aberrations and gene 
rearrangements which provide further support for 
their classification as separate entities from their 
nodal types. 
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Identity 
Lymphoma is classified as primary cutaneous 
lymphoma (PCL) when the malignant lymphocyte 
proliferation is limited to the skin with no 
involvement of lymph nodes, bone marrow or 
viscera at diagnosis. PCLs are the most frequent 
extra-nodal lymphomas, with incidence around 10 
cases per million individuals per year, from which 
25-30% are primary cutaneous B-cell lymphomas 
(PCBCL) (Kempf W et al 2014 Mar). PCBCLs are 
characterized by great biological and clinical 
variability among its various subtypes (Sokotowska-
Wojdyto 2015). The classification was 
revolutionized by the consensus statement between 
the World Health Organization (WHO) and 
European Organization for the Research and 
Treatment of Cancer in 2005. The distinct cutaneous 
B-cell lymphoma entities are discussed here.  
 Classification:   
Currently, the CBCL classified according to WHO-
EORTC classification into three main subtypes 
(Swerdlow 2017) which are the following: 
 Primary cutaneous follicle center lymphoma 
(PCFCL) 
 Primary cutaneous marginal zone lymphoma 
(PCMZL) 
 Primary cutaneous diffuse large B-cell lymphoma 
(PCDLBCL)  
The WHO classification was updated in 2018 to 
include additional provisional entity, EBV-positive 
mucocutaneous ulcer and to recognize 2 subsets of 
PCMZL (Willemze 2019). Intravascular large B-cell 
lymphoma was also included as part of CBCL. 
While it has a 'cutaneous' variant (Ferreri 2004), this 
entity will not be discussed further in this review. It 
is critical to distinguish PCBCL from systemic B cell 
lymphomas with secondary skin involvement 
because the clinical behaviors, prognosis, and 
management differ considerably. 
Clinics and pathology 
Phenotype/cell stem origin 
 Cell Origin:  CBCL, by definition, is of B-cell 
origin. All entities express mature B-cell phenotype. 
Cells are positive for a variety of B-cell markers like 
surface immunoglobulins (sIg), pan B-cell antigens 
like CD19, CD20 and/or CD79b. Each entity may be 
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associated with certain immunophenotypes as 
demonstrated below under Pathology.   
Putative normal counterpart of PCMZL is post 
germinal center marginal zone B-lymphocytes of 
secondary lymphoid follicles. PCMZL is considered 
a type of extranodal marginal zone lymphoma of 
mucosa-associated lymphoid tissue (MALT).  
The PCFCL is thought to arise from mature germinal 
center cells B-cell while the PCDLBCL, leg-type 
arises from peripheral B-cells of post germinal 
center origin (Hoefnagel 2005). 
Embryonic origin 
The exact etiology and pathogenesis of CBCL is 
poorly understood. However, dysregulation of an 
antigen-driven response and infectious etiologies 
have been proposed in some cases. Dysregulation of 
germinal center B-cell proliferation might play a role 
in PCFCL. Infection by Borrelia burgdorferi has 
been implicated as etiological factor in PCMZL 
since DNA sequences of this organism were found 
in skin lesions of some PCMZL cases. However, 
such association may be geography- dependent since 
some studies have questioned this association 
(Ponzoni 2011). 
Epidemiology 
Approximately 25% of all non-Hodgkin lymphoma 
(NHL) cases will present at an extranodal site 
without systemic involvement. The overall incidence 
of primary cutaneous lymphomas in Western 
countries is estimated to be 0.5 to 1 case per 100,000 
people annually. The PCBCLs make up 
approximately 25% of all primary cutaneous 
lymphomas, the remainder predominantly T-cell 
lymphomas (Swerdlow 2013). The incidence varies 
geographically with lower rates in some countries 
(Abeldano 2018). PCMZL represents an indolent 
type of CBCL comprising approximately 7% of PCL 
and approximately 25% of CBCL. In the revised 
WHO classification of lymphoma, PCMZL is 
considered under extranodal marginal zone 
lymphoma of MALT type (Swerdlow 2016, 
Swerdlow 2017). PCMZL usually presents in the 
fifth decade of life, although the disease has been 
diagnosed in children (Kempf 2014 Aug). Men are 
diagnosed approximately twice as often as women. 
Most cases occur in non-Hispanic Whites (Kempf 
2014 Mar).  
The PCFCL is the most common PCBCL, 
accounting for approximately 60% of such cases 
(Willemze 2005, Willemzie 2019). It is primarily a 
disease of middle aged to older patients (median age 
at onset is 51) and a male to female ratio of 
approximately 1.5:1 (Zinzani 2006, Bradford 2009, 
Swerdlow 2017). PCLBCL, leg type comprises 5% 
of all cutaneous lymphomas and 20% of all 
PCBCLs. The median age at presentation is in the 
mid to late seventies and is more common in females 
than in males with a male to female ratio of 1:3-4 
(Swerdlow 2017). In contrast to the previous 2 
entities, PCDLBCL-leg type is an aggressive disease 
and is associated with poor prognosis. 
Clinics 
Clinically, PCL is defined as non-Hodgkin's 
lymphoma (NHL) presenting in the skin with no 
evidence of extra-cutaneous disease at time of 
diagnosis for 6 months following initial diagnosis 
(Willemze 2005). This definition requires that 
clinicians conduct careful staging work up according 
to standard guidelines (Cheson 2014) to document 
the absence of disease elsewhere before designation 
as PCL. If disease is found elsewhere, like lymph 
nodes or other extranodal sites, then skin 
involvement is secondary, and the patient is 
designated to have stage IV lymphoma with skin 
involvement. As described below, none of the CBCL 
types has a pathognomonic appearance skin lesions 
and a biopsy of representative lesion is required to 
establish the diagnosis.  
Figure 1:  A: PCFCL in forehead and scalp; B: PCFCL in 
upper back. Skin lesions range between plaques, papules 
and tumor nodules which are reddish in color. C: 
PCDLBCL in left leg. Multiple plaque lesions 
PCMZL manifests as solitary or multiple reddish, 
dome-shaped papules, nodules or erythematous 
plaques. The disease frequently presents in the trunk 
or extremities, and to a lesser extent in the head and 
neck area.  
PCFCL commonly presents in the scalp and 
forehead (Figure 1A) but can involve the trunk and 
limbs. Lesions can be solitary or grouped and vary 
from pink papules to violaceous nodules. PCFCL 
that presents in the trunk (Figure 1B) used to be 
called reticulohistiocytoma of the dorsum or Crosti 
lymphoma' (Berti 1988).  
PCDLBCL can be divided into 2 distinct sub-
entities: PCDLBCL-leg type, and PCDLBCL-other 
(Paulli 2012). The leg type (LT) is commonly seen 
in older women and usually presents in the lower 
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extremities although other sites of the body can be 
involved.  
The disease presents as rapidly growing solitary or 
multiple nodules or plaques (Figure 1C). The lesions 
are pink, red, bluish-red or violaceous in color.  
Unlike PCMZL and PCFCL, DLBCL-LT is an 
aggressive disease where most patients will have 
local recurrence and/or extracutaneous progression 
and poor overall survival (Grange 2007). 
PCDLBCL-other includes T-cell/histiocyte-rich 
DLBCL, plasmablastic lymphoma, intravascular 
large B-cell lymphoma and other types that are 
distinct from PCDLBCL-LT. 
Pathology 
The diagnosis is established by performing a biopsy 
of the skin lesions, through histological 
examinations, complemented by immunophenotypic 
and genotypic studies (Swerdlow 2013; Kempf 
2014). Histologically, three growth patterns have 
been recognized in PCFCL: follicular, diffuse or 
follicular and diffuse; the diffuse pattern is most 
frequent (Figure 2A).  
Cells are small lymphocytes (centrocytes) with few 
large cells (centroblasts or immunoblasts) (Figure 
2B). Immunohistochemical stain typically shows the 
lymphocytic infiltrate to be positive for CD20 and 
BCL6 but is generally negative for CD10 and BCL2 
(Figure 4C-F). 
Figure 2:  A, Skin biopsy of a patient with PCFCL. H & E stain; B, PCFCL, diffuse growth pattern. H & E; C, PCFCL, 
Immunohistochemical (IHC) stain of CD20 showing strong positive staining of lymphocytic infiltrate; D, PCFCL, IHC showing 
diffusely positive staining for BCL6; E, PCFCL, IHC showing positive BCL2 stain in a pattern similar to CD3 staining; 4F: PCFCL, 
IHC showing negative stain for CD10 
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Some cases may express BCL2 in a minority of 
malignant cells but staining is usually faint and is 
weaker than admixed reactive T-cells. CD10 may 
also be positive in some cases of follicular growth 
pattern but is negative in cases of diffuse growth 
pattern. Strong expression of BCL2 and CD10 
should raise suspicion that skin involvement is 
secondary to a nodal follicular lymphoma rather than 
PCFCL. T-cell markers and CD30 are negative; 
however, CD3 may stain reactive T-cells which may 
be numerous.  
Histopathologic findings of PCMZL include a 
nodular or diffuse nonepidermotropic infiltrate 
composed of small to medium-size lymphoid cells 
(Figure 3A). The nuclei are indented, and cells have 
abundant cytoplasm. Lymphoid cell infiltrate can be 
admixed with various number of plasma cells and 
reactive T-cells. Asian cases with PCMZL were 
reported to show tissue eosinophilia in tumor 
specimens, a feature not found in cases from 
Germany or United States (Takino 2008). 
Immunophenotypically, PCMZL tumor cells express 
B-cell markers like CD20 (Figure 3B), and CD79a. 
CD3 highlights reactive T-cells which sometimes are 
present in larger numbers than the malignant B-cells 
(Figure 3C). In such cases, it is important to 
document B-cell monoclonality which can be 
demonstrated using IHC techniques like in situ 
hybridization for immunoglobulin light chain 
staining. Malignant B-cells are negative for germinal 
center markers like CD10 and BCL6 (Figure 3D).  
PCDLBCL, LT is characterized histologically by 
diffuse infiltrate covering the entire dermis but 
usually spares a thin subepidermal grenz zone and 
the epidermis (Figure 4A). Tumor cell infiltrate 
destroys adnexal structures and extends to 
subcutaneous tissue. As the name implies, cells are 
large B-cells (also referred to as centroblasts or 
immunoblasts) (Figure 4B). The immunophenotype 
of tumor cells typically is positive for CD19, CD20 
(Figure 4C), CD79a, BCL2, and MUM1 (Figure 
4D). Cells are usually negative for CD3 (Figure 4E), 
CD5, CD21, CD138, CD10, and cyclin D1. Cell 
proliferation is high (Figure 4F). Strong expression 
of BCL2 and MUM1 in PCDLBCL, LT helps 
distinguish this entity from diffuse type PCFCL 
which is negative for these 2 markers.
Figure 3; A: PCMZL, Skin biopsy showing deep dermal lymphocytic infiltrate; B: PCMZL. CD20 stain; C: PCMZL. CD3 stain 
showing abundant reactive T-cells; D: PCMZL. BCL6 stain, negative 
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Figure 4; A:  PCDLBCL, LT. H & E stain, low power showing diffuse infiltration of the dermis with sparing of the epidermis and 
subepidermal layers; B: PCDLBC6BL, LT. Large cells (centroblasts) with irregular vesicular nuclei and few apoptotic cells; C: 
PCDLBCL, LT. Strongly positive CD20 membrane stain; D: PCDLBCL, LT. MUM1 stain. Most of the large lymphoma cells are 
positive. E: PCDLBCL, LT. CD3 stain showing few reactive T-cells. The large cells are negative. F: PCDLBCL, LT. Ki 67. More 
than 90% of cells show positive nuclear stain 
.
Treatment 
The choice of therapy of CBCL relies on correct 
histopathologic classification and the exclusion of 
systemic disease. The European Organization for 
Research and Treatment of Cancer (EORTC) and 
International Society for Cutaneous Lymphoma 
(ISCL) have published consensus recommendations 
for the management of CBCL (Sneff 2008). For 
localized PFCL and PCMZL, the disease is managed 
by local therapy, such as radiation or surgical 
excision. Observation is appropriate for 
asymptomatic multifocal presentation of these 
categories given their indolent nature. However, for 
symptomatic, progressive or relapsed disease, a 
variety of systemic therapies are available. The 
simplest is anti-CD20 (rituximab) monotherapy in a 
standard dose/schedule. 
Prognosis 
Subclassification and the extent of cutaneous 
involvement were identified as the most relevant 
prognostic factors in CBCL (Zinzani 2006). PCFCL 
and PCMZL are indolent types of cutaneous 
lymphoma with excellent prognosis. The 5 year 
survival rate is 90-95%.  However, like their nodal 
counterparts, they have tendency to recur in up to 
40% of cases but dissemination to extracutaneous 
sites is rare (Chan 2016). Both PCFCL and PCMZL 
can transform to DLBCL with a more aggressive 
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behavior. The PCDLBCL, LT on the other hand is 
an aggressive disease with a 5 year survival of 20-
50%. Mutation of the Myeloid Differentiation 
(MYD88) Primary Response gene (L265P) is 
frequently found in PCDLBCL, LT and is associated 
with inferior prognosis (Pham-Ledard 2014). 
Genetics 
Molecular study of immunoglobulin genes 
rearrangement is detected in all subtypes that are 
valuable to document clonality and differentiate 
PCBCL from pseudolymphomas. Until recently, 
cytogenetic studies had limited value in the 
diagnosis of PCBCL, since recurrent chromosomal 
and molecular alterations were not well 
characterized. Approximately 25% of PCMZLs 
demonstrate the t(14;18) (IGH/MALT1) 
translocation. The t(11;18) and t(3;14)orted in 7% 
and 10% of PCMZLs, respectively, whereas the 
t(1;14) translocation has not been identified in 
PCMZL (Abdul-Wahab, 2014). MYD88 mutations 
have been found in 50% of non-class-switched cases 
of PCMZL, but not in class-switched cases (Wobser 
2017). Recurrent mutations in FAS were found in 24 
of 38 (63%) patients with PCMZL (Maurus 
2018).The overexpression of microRNAs MIR 155 
and MIR150 is another molecular feature unique to 
PCMZL, and this feature may also predict longer 
progression-free survival.  
On the contrary, the PCDLBCL, LT shows many 
genetic similarities with diffuse large B cell 
lymphomas arising at other sites. Interphase FISH 
analysis frequently shows translocation involving 
MYC/8q24, BCL6/3q27 and IGH/14q32 genes in 
PCDLBCL, LT but not in patients with a PCFCL 
(Hallermann 2004 July). Comparative genomic 
hybridization (CGH), using microarrays and 
subsequently confirmed by FISH analysis showed 
that most of PCDLBCL, LT cases had chromosomal 
aberrations including gains in chromosomes 1, 2, 3, 
7, and 12, losses in 6q, 13, 14, and 18q (Dijkman 
2006).  In contrast, PCFCL had fewer imbalances 
and lacked translocations affecting the IGH locus 
(Hallermann June 2004). Most PCFCL do not 
exhibit t(14;18)(q32;q21) that determines 
BCL2/IGH rearrangement and features of nodal 
follicular lymphoma (Abdul-Wahab 2014).  The 
most recurrent alterations in PCFCL were high-level 
DNA amplifications at 2p16.1 (63%) and deletion of 
chromosome 14q32.33 (68%). FISH analysis 
confirmed REL amplification in patients with gains 
at 2p16.1. The same study showed that PCDLBCL, 
LT have a high-level DNA amplification of 
18q21.31-q21.33 (67%), including the BCL2 and 
MALT1 genes as confirmed by FISH. This may 
explain the strong BCL2 expression in these cases 
although lacking t(14;18) (BCL2/IGH) 
translocation. Recurrent homozygous DNA 
deletions in region 9p21.3 which contains CDKN2A, 
CDKN2B and NSG-x genes are found in 67% of 
PCDLBCL, LT cases but not in any of the PCFCL 
patients (Belaud-Rotureau 2008). In addition, some 
PCDLBCL, LT (17%) had a complete 
hypermethylation of CDKN2A gene promoter. In 
contrast, deletions of chromosome 9p21.3 
containing the CDKN2A and CDKN2B gene loci, 
and MYD88 mutations are not or only rarely found 
in PCFCL. In conclusion, these studies clearly 
demonstrate distinct chromosomal and genomic 
aberrations in PCFCL and PCDLBCL, LT which 
provides further support for their categorization in 
the WHO-EORTC classification as separate entities. 
Finally, loss of chromosome 9p21.3 might prove to 
be an important prognostic marker in PCDLBCL, LT 
associated with inferior outcome (Sneff 2009) 
although confirmation on a larger group of patients 
is required. PCFCL shows the gene expression 
profile of germinal center-like large B cell 
lymphomas, and often shows amplifications of the 
REL gene (Hoefnagel 2005). Deletion of 
chromosome 14q32.33 has been also reported in 
PCFCL (Dijkman 2006). 
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